Peter Greenleaf, Aurinia CEO
March 3, 2022 01:09 PM EST
Pharma
FDA+
Marketing

Au­rinia faces chop­py wa­ters amid low­er-than-ex­pect­ed 2022 guid­ance and patent chal­lenge on Lup­ky­nis

Beth Snyder Bulik

Senior Editor

A new patent chal­lenge to Au­rinia Phar­ma­ceu­ti­cals’ lu­pus nephri­tis drug Lup­ky­nis is adding to the bio­phar­ma’s woes this week. Sun Phar­ma­ceu­ti­cal is chal­leng­ing Au­rinia’s treat­ment …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times